利用重组CD55-CD46融合蛋白阻断大疱性类天疱疮中的补体激活。 - Suppr

Suppr

超能文献

Blockade of complement activation in bullous pemphigoid by using recombinant CD55-CD46 fusion protein.

作者信息

Qiao Pei, Luo Yi-Xin, Zhi Da-Long, Wang Gang, Dang Er-Le

机构信息

Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.

出版信息

Chin Med J (Engl). 2021 Apr 5;134(7):864-866. doi: 10.1097/CM9.0000000000001312.

DOI:10.1097/CM9.0000000000001312

PMID:33797471

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8104184/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41b5/8104184/f203f59388fd/cm9-134-864-g001.jpg

相似文献

Blockade of complement activation in bullous pemphigoid by using recombinant CD55-CD46 fusion protein.利用重组CD55-CD46融合蛋白阻断大疱性类天疱疮中的补体激活。

Chin Med J (Engl). 2021 Apr 5;134(7):864-866. doi: 10.1097/CM9.0000000000001312.

Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.siRNA 抑制膜补体抑制剂表达（CD46、CD55、CD59）可使肿瘤细胞在体外对补体攻击敏感。

Curr Cancer Drug Targets. 2010 Dec;10(8):922-31. doi: 10.2174/156800910793357952.

Dysregulation of mCD46 and sCD46 contribute to the pathogenesis of bullous pemphigoid.mCD46 和 sCD46 的失调导致大疱性类天疱疮的发病机制。

Sci Rep. 2017 Mar 10;7(1):145. doi: 10.1038/s41598-017-00235-3.

CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.CRISPR/Cas9技术构建的人CD46、CD55和CD59基因敲除细胞系作为补体研究工具

J Immunol Methods. 2018 May;456:15-22. doi: 10.1016/j.jim.2018.02.004. Epub 2018 Feb 12.

Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation.嵌合CD46/衰变加速因子（DAF）分子揭示了DAF的SCR1在调节补体激活中的隐秘功能作用。

Mol Immunol. 2000 Aug-Sep;37(12-13):687-96. doi: 10.1016/s0161-5890(01)00002-5.

Human CD46 rather than CD55 is a key element in protection against complement activation in vitro.

Transplant Proc. 2000 Aug;32(5):916-8. doi: 10.1016/s0041-1345(00)01036-8.

Decreased expression levels of complement regulator CD55 contribute to the development of bullous pemphigoid.补体调节蛋白CD55表达水平降低促成大疱性类天疱疮的发展。

Oncotarget. 2017 Sep 23;9(85):35517-35527. doi: 10.18632/oncotarget.21216. eCollection 2018 Oct 30.

Relative Contribution of Cellular Complement Inhibitors CD59, CD46, and CD55 to Parainfluenza Virus 5 Inhibition of Complement-Mediated Neutralization.细胞补体抑制剂 CD59、CD46 和 CD55 对副流感病毒 5 抑制补体介导的中和作用的相对贡献。

Viruses. 2018 Apr 25;10(5):219. doi: 10.3390/v10050219.

The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.补体受体 CD46、CD55 和 CD59 受头颈部癌症肿瘤微环境调控，以促进逃避补体攻击。

Eur J Cancer. 2014 Aug;50(12):2152-61. doi: 10.1016/j.ejca.2014.05.005. Epub 2014 Jun 7.

Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.胃肠道癌细胞上补体抗性因子CD46、CD55和CD59的频繁表达限制了单克隆抗体17-1A的治疗潜力。

J Surg Oncol. 1997 Mar;64(3):222-30. doi: 10.1002/(sici)1096-9098(199703)64:3<222::aid-jso9>3.0.co;2-c.

引用本文的文献

Recent advances in the genetics and innate immune cells of bullous pemphigoid.大疱性类天疱疮的遗传学和固有免疫细胞的最新进展。

Front Immunol. 2025 Jun 18;16:1530407. doi: 10.3389/fimmu.2025.1530407. eCollection 2025.

Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.推进大疱性类天疱疮的治疗：新型治疗靶点和方法的全面综述。

Clin Rev Allergy Immunol. 2023 Dec;65(3):331-353. doi: 10.1007/s12016-023-08973-1. Epub 2023 Oct 28.

A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.大疱性类天疱疮相关免疫途径及新型治疗靶点综述

J Clin Med. 2022 May 18;11(10):2856. doi: 10.3390/jcm11102856.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验